IMRX Immuneering Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: IMRX

Price (delayed)

$4.545

Market cap

$294.05M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.06

Enterprise value

$250.46M

?
Relative Growth: Rel. Growth: 15
Relative Strength: Rel. Strength: 65
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 10
Highlights
The quick ratio has soared by 84% from the previous quarter
The EPS is up by 46% year-on-year and by 17% since the previous quarter
Immuneering's equity has decreased by 5% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of IMRX

IMRX stock price

How has the Immuneering stock price performed over time
Intraday
-0.11%
1 week
-10.18%
1 month
-15.6%
1 year
131.89%
YTD
-30.93%
QTD
-13.76%

Financial performance

How have Immuneering's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$59.23M
Net income
-$54.44M
Gross margin
N/A
Net margin
N/A
The net income has increased by 12% year-on-year and by 2.8% since the previous quarter
The operating income is up by 8% year-on-year

Price vs fundamentals

How does IMRX's price correlate with its fundamentals

Growth

What is Immuneering's growth rate over time

Valuation

What is Immuneering stock price valuation
P/E
N/A
P/B
1.42
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 46% year-on-year and by 17% since the previous quarter
IMRX's P/B is 35% less than its last 4 quarters average of 2.2 and 29% less than its 5-year quarterly average of 2.0
Immuneering's equity has decreased by 5% from the previous quarter

Efficiency

How efficient is Immuneering business performance
IMRX's return on invested capital has surged by 88% year-on-year and by 61% since the previous quarter
The ROE has soared by 73% YoY and by 26% from the previous quarter
The ROA has soared by 70% year-on-year and by 25% since the previous quarter

Dividends

What is IMRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IMRX.

Financial health

How did Immuneering financials performed over time
The current ratio has surged by 85% since the previous quarter
The quick ratio has soared by 84% from the previous quarter
The debt is 98% smaller than the equity
IMRX's debt to equity has dropped by 80% year-on-year
The debt has declined by 9% year-on-year and by 2.5% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.